Needham reiterated coverage of Steris with a rating of Buy and set a new price target of $263.00 from $254.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $230.00 → $260.00 | Neutral → Overweight | Piper Sandler |
| 2/6/2024 | $253.00 | Overweight | KeyBanc Capital Markets |
| 5/30/2023 | $206.00 | Equal-Weight | Morgan Stanley |
| 4/14/2023 | $215.00 → $197.00 | Overweight → Neutral | Piper Sandler |
| 9/23/2022 | Buy → Hold | Needham | |
| 7/14/2022 | $240.00 | Overweight | Piper Sandler |
| 4/7/2022 | $275.00 | Outperform | Wolfe Research |
| 2/14/2022 | $250.00 → $270.00 | Market Outperform | JMP Securities |
Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously
KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00
Morgan Stanley initiated coverage of Steris with a rating of Equal-Weight and set a new price target of $206.00
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7%As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14Fiscal 2025 outlook reiterated DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) -- - STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing operations for the second quarter of fiscal 2025 increased 7% to $1.3 billion compared with $1.2 billion in the second quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the second quarter increased 7
DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on December 19, 2024, to shareholders of record at the close of business on November 19, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences produ
DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 second quarter financial results at 9:00 a.m. ET on November 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on November 6, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 7,
10-Q - STERIS plc (0001757898) (Filer)
8-K - STERIS plc (0001757898) (Filer)
144 - STERIS plc (0001757898) (Subject)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
These large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries (NYSE:TEVA) shares surged 16.24% after the company reported mixed Q1 financial results and announced results from the efficacy portion of the Phase 3 SOLARIS trial of TEV-‘749 in adult patients with schizophrenia compared to placebo. Toast, Inc. Class A (NYSE:TOST) shares increased 14.71% on strong first-quarter 2024 financial results, with revenue of $1.075 billion, beating the estimates of $1.041 billion. Several analysts raised the price target on the stock. Applovin Corporation (NASDAQ:APP) shares were up 13.28% after the company reported better-than-expe
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Neutral and raises the price target from $220 to $225.
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.
Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7%As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14Fiscal 2025 outlook reiterated DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) -- - STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing operations for the second quarter of fiscal 2025 increased 7% to $1.3 billion compared with $1.2 billion in the second quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the second quarter increased 7
DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on December 19, 2024, to shareholders of record at the close of business on November 19, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences produ
DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 second quarter financial results at 9:00 a.m. ET on November 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on November 6, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 7,
DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal
David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W